Quillivant Xr generic
Quillivant Xr is an anti-ADHD drug owned by Nextwave. It contains the active ingredient methylphenidate hydrochloride and was first authorized for market use on 27th September, 2012. The drug is available in suspension, extended release oral dosage forms and has a total of 7 patents.
When will Quillivant Xr generic be available?
As of now, all patents of Quillivant Xr are still valid. The last patent is expected to expire on 15th February, 2031. After this date, generic versions of Quillivant Xr may become available unless there are other factors, such as litigation or additional patents, that extend the exclusivity period.
Quillivant Xr uses
Quillivant Xr is primarily used for treating patients with conditions susceptible to treatment with methylphenidate, such as attention deficit hyperactivity disorder (ADHD). Its methylphenidate hydrochloride content contributes to its efficacy in treating these conditions by acting on the nervous system to increase attention and decrease impulsiveness and hyperactivity in patients who are overactive, cannot concentrate for very long, or are easily distracted.
Quillivant Xr patent expiration
Quillivant Xr is protected by 7 patents, the last of which is set to expire on 15th February 2031. These patents primarily pertain to orally effective methylphenidate extended release powder and aqueous suspension product, seminal to Quillivant Xr's formulation. Below are the details of the patent: